Invention Grant
- Patent Title: Early-stage Alzheimer's disease autoantibody biomarkers, target antigens and diagnostic uses thereof
-
Application No.: US16061534Application Date: 2016-12-14
-
Publication No.: US11619632B2Publication Date: 2023-04-04
- Inventor: Robert G. Nagele
- Applicant: ROWAN UNIVERSITY
- Applicant Address: US NJ Glassboro
- Assignee: ROWAN UNIVERSITY
- Current Assignee: ROWAN UNIVERSITY
- Current Assignee Address: US NJ Glassboro
- Agency: Fox Rothschild LLP
- International Application: PCT/US2016/066645 WO 20161214
- International Announcement: WO2017/106338 WO 20170622
- Main IPC: G01N33/564
- IPC: G01N33/564 ; G01N33/68
Abstract:
The present invention provides methods, compositions, and kits for the detection of Early-Stage Alzheimer's disease (AD) autoantibody biomarkers, for the diagnosis of Early-Stage AD, for the identification of a subject at risk for developing Early-Stage AD, and/or for the generation of patient-specific Early-Stage AD autoantibody biomarker profiles.
Public/Granted literature
- US20200340990A1 EARLY-STAGE ALZHEIMER'S DISEASE AUTOANTIBODY BIOMARKERS, TARGET ANTIGENS AND DIAGNOSTIC USES THEREOF Public/Granted day:2020-10-29
Information query
IPC分类:
